GlycoBac announces partnership with MilliporeSigma
GlycoBac has partnered with MilliporeSigma to facilitate the distribution of our Sf-RVN cell line for commercial vaccine and gene therapy vector production. In addition to distributing Sf-RVN cells through a cGMP cell bank, MilliporeSigma will offer a chemically defined medium formulation specially designed for Sf-RVN cells. See the announcement from MilliporeSigma
|
GlycoBac study highlighted in Virology
|
GlycoBac researchers recently published a peer-reviewed study on genetic variation and infectivity of Sf-rhabdovirus from different Sf cell lines in the December issue of Virology (Vol. 512, pp. 234-245)
|
This is the first published study to directly demonstrate Sf-rhabdoviruses can establish persistent, productive infections in Sf cells. It is | | also the first study to directly demonstrate different Sf-rhabdovirus variants, including variants with a large deletion, are infectious for Sf cells.
|
|
We thank the editors for recognizing the value of our work!
|
GlycoBac develops Sf-RVN, a new Sf-rhabdovirus-free S. frugiperda cell line for recombinant protein production
|
|
Sf-RVN is an Sf-rhabdovirus-negative S. frugiperda cell line. In 2014, Sf-rhabdovirus was discovered as a contaminant of all S. frugiperda cell lines tested (Ma et al., J. Virol. 88:6576).
|
GlycoBac is currently providing Sf-RVN cells to interested parties under commercial Materials Transfer Agreements (for evaluation) and/or licensing agreements (for application) in various fields of use.
|
Please contact Dr. Jarvis directly for additional information.
|
Read another peer-reviewed paper published in the Elsevier journal 'Biologicals' about endogenous viral elements discovered by GlycoBac researchers in Sf-RVN and other cell lines.
|
Sf-RVN cells are a safer alternative to commonly used S. frugiperda cell lines. Listen to Prof. Dr. Jarvis talk about Sf-RVN cells and how they compare to Sf9 cells:
|
|
|
|
